Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Laarhoven, H.W.M. van"'
Autor:
Suurmeijer, J.A., Soer, E.C., Dings, M.P.G., Kim, Y., Strijker, M., Bonsing, B.A., Brosens, L.A.A., Busch, O.R., Groen, J.V., Halfwerk, J.B.G., Slooff, R.A.E., Laarhoven, H.W.M. van, Molenaar, I.Q., Offerhaus, G.J.A., Morreau, J., Vijver, M.J. van de, Sarasqueta, A.F., Verheij, J., Besselink, M.G., Bijlsma, M.F., Dijk, F., Dutch Pancreatic Cancer Grp
Publikováno v:
British Journal of Surgery, 109(11), 1150-1155. OXFORD UNIV PRESS
The British journal of surgery, 109(11), 1150-1155. John Wiley and Sons Ltd
Dutch Pancreatic Cancer Group 2022, ' Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study ', The British journal of surgery, vol. 109, no. 11, pp. 1150-1155 . https://doi.org/10.1093/bjs/znac272
The British journal of surgery, 109(11), 1150-1155. John Wiley and Sons Ltd
Dutch Pancreatic Cancer Group 2022, ' Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study ', The British journal of surgery, vol. 109, no. 11, pp. 1150-1155 . https://doi.org/10.1093/bjs/znac272
Background The recently identified classical and basal-like molecular subtypes of pancreatic cancer impact on overall survival (OS). However, the added value of routine subtyping in both clinical practice and randomized trials is still unclear, as mo
Autor:
Jong, E.J.M. de, Janssen, Q.P., Simons, T.F.A., Besselink, M.G., Bonsing, B.A., Bouwense, S.A.W., Geurts, S.M.E., Homs, M.Y.V., Meijer, V.E. de, Tjan-Heijnen, V.C.G., Laarhoven, H.W.M. van, Valkenburg-van Iersel, L.B.J., Wilmink, J.W., Geest, L.G. van der, Koerkamp, B.G., Vos-Geelen, J. de, Dutch Pancreatic Canc Grp
Publikováno v:
the Dutch Pancreatic Cancer Group 2021, ' Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma ', International Journal of Cancer . https://doi.org/10.1002/ijc.33916
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.
The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC-4 trial. Real-world data on the effectiveness of gemcitabine plus capecitabine (GEMCAP), in patients ineligibl
Autor:
Zijlstra, M., Roij, J. van, Henselmans, I., Laarhoven, H.W.M. van, Creemers, G.J., Vreugdenhil, G., Kuip, E.J.M., Raijmakers, N.J.H., Grp, eQuiPe study
Publikováno v:
Supportive Care in Cancer, 31
Supportive Care in Cancer, 31, 3
Supportive Care in Cancer, 31, 3
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::045ec88bf1dde763f60ea18a1d2f3a6f
http://hdl.handle.net/2066/290564
http://hdl.handle.net/2066/290564
Autor:
Veen, A. van der, Meulen, M.P. van der, Seesing, M.F.J., Brenkman, H.J.F., Haverkamp, L., Luyer, M.D.P., Nieuwenhuijzen, G.A.P., Stoot, J.H.M.B., Tegels, J.J.W., Wijnhoven, B.P.L., Lagarde, S.M., Steur, W.O. de, Hartgrink, H.H., Kouwenhoven, E.A., Wassenaar, E.B., Draaisma, W.A., Gisbertz, S.S., Peet, D.L. van der, Laarhoven, H.W.M. van, Frederix, G.W.J., Ruurda, J.P., Hillegersberg, R. van, Laparoscopic Vs Open Gastrectomy G
Publikováno v:
JAMA Surgery, 158(2), 120-128. AMER MEDICAL ASSOC
IMPORTANCE Laparoscopic gastrectomy is rapidly being adopted worldwide as an alternative to open gastrectomy to treat gastric cancer. However, laparoscopic gastrectomy might be more expensive as a result of longer operating times and more expensive s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ec24387b6032a1f23581361b0ea7a229
http://hdl.handle.net/1887/3567033
http://hdl.handle.net/1887/3567033
Autor:
Luijten, J., Vissers, Pauline A.J., Brom, L., Bièvre, M. de, Buijsen, J., Rozema, T., Mohammad, N.H., Duijvendijk, P. van, Kouwenhoven, E.A., Eshuis, W.J., Rosman, C., Siersema, P.D., Laarhoven, H.W.M. van, Verhoeven, R.H.A., Nieuwenhuijzen, G.A., Westerman, M.J.
Publikováno v:
BMC Health Services Research, 22(1):527. BioMed Central
BMC health services research, 22(1):527. BioMed Central
BMC Health Services Research, 22
BMC Health Services Research, 22(1):527. BioMed Central Ltd
Luijten, J C H B M, Vissers, P A J, Brom, L, de Bièvre, M, Buijsen, J, Rozema, T, Mohammad, N H, van Duijvendijk, P, Kouwenhoven, E A, Eshuis, W J, Rosman, C, Siersema, P D, van Laarhoven, H W M, Verhoeven, R H A, Nieuwenhuijzen, G A P & Westerman, M J 2022, ' Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study ', BMC Health Services Research, vol. 22, no. 1, 527 . https://doi.org/10.1186/s12913-022-07845-2
BMC Health Services Research, 22, 1
BMC health services research, 22(1):527. BioMed Central
BMC Health Services Research, 22
BMC Health Services Research, 22(1):527. BioMed Central Ltd
Luijten, J C H B M, Vissers, P A J, Brom, L, de Bièvre, M, Buijsen, J, Rozema, T, Mohammad, N H, van Duijvendijk, P, Kouwenhoven, E A, Eshuis, W J, Rosman, C, Siersema, P D, van Laarhoven, H W M, Verhoeven, R H A, Nieuwenhuijzen, G A P & Westerman, M J 2022, ' Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study ', BMC Health Services Research, vol. 22, no. 1, 527 . https://doi.org/10.1186/s12913-022-07845-2
BMC Health Services Research, 22, 1
Background Among esophagogastric cancer patients, the probability of having undergone treatment with curative intent has been shown to vary, depending on the hospital of diagnosis. However, little is known about the factors that contribute to this va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117dd973d1ce278dc51ed328563ececf
https://research.vumc.nl/en/publications/93dc58ec-d63f-49d3-9298-4b8e5a00878f
https://research.vumc.nl/en/publications/93dc58ec-d63f-49d3-9298-4b8e5a00878f
Autor:
Boorn, Hector G. van den, Abu-Hanna, A., Mohammad, Nadia Haj, Hulshof, M.C.C., Gisbertz, S.S., Klarenbeek, B.R., Verhoeven, R.H.A., Zwinderman, Koos H., Laarhoven, H.W.M. van
Publikováno v:
Journal of the National Comprehensive Cancer Network, 19, 403-410
Journal of the National Comprehensive Cancer Network, 19, 4, pp. 403-410
Journal of the National Comprehensive Cancer Network, 19, 4, pp. 403-410
Contains fulltext : 233871.pdf (Publisher’s version ) (Closed access)
Autor:
Latenstein, A.E.J., Roessel, S. van, Geest, L.G.M. van der, Bonsing, B.A., Dejong, C.H.C., Koerkamp, B.G., Hingh, I.H.J.T. de, Horns, M.Y.V., Klaase, J.M., Lemmens, V., Molenaar, I.Q., Steyerberg, W., Stommel, M.W.J., Busch, O.R., Eijck, C.H.J. van, Laarhoven, H.W.M. van, Wilmink, J.W., Besselink, M.G., Dutch Pancreatic Canc Grp
Publikováno v:
Annals of Surgical Oncology, 27, 2516-2524
Annals of Surgical Oncology, 27(7), 2516-2524. Springer New York
Annals of Surgical Oncology
Annals of Surgical Oncology, 2516-2524. SPRINGER
ISSUE=7;STARTPAGE=2516;ENDPAGE=2524;ISSN=1068-9265;TITLE=Annals of Surgical Oncology
Annals of Surgical Oncology, 27, 2516-2524. SPRINGER
Annals of Surgical Oncology, 27, 7, pp. 2516-2524
Annals of Surgical Oncology, 27(7), 2516-2524. Springer, Cham
Annals of surgical oncology, 27(7), 2516-2524. Springer New York
Annals of Surgical Oncology, 27(7), 2516-2524. Springer New York
Annals of Surgical Oncology
Annals of Surgical Oncology, 2516-2524. SPRINGER
ISSUE=7;STARTPAGE=2516;ENDPAGE=2524;ISSN=1068-9265;TITLE=Annals of Surgical Oncology
Annals of Surgical Oncology, 27, 2516-2524. SPRINGER
Annals of Surgical Oncology, 27, 7, pp. 2516-2524
Annals of Surgical Oncology, 27(7), 2516-2524. Springer, Cham
Annals of surgical oncology, 27(7), 2516-2524. Springer New York
Background Conditional survival is the survival probability after already surviving a predefined time period. This may be informative during follow-up, especially when adjusted for tumor characteristics. Such prediction models for patients with resec
Autor:
Mackay, T.M., Smits, F.J., Roos, D., Bonsing, B.A., Bosscha, K., Busch, O.R., Creemers, G.J., Dam, R.M. van, Eijck, C.H.J. van, Gerhards, M.F., Groot, J.W.B. de, Koerkamp, B.G., Mohammad, N.H., Harst, E. van der, Hingh, I.H.J.T. de, Homs, M.Y.V., Kazemier, G., Liem, M.S.L., Meijer, V.E. de, Molenaar, I.Q., Nieuwenhuijs, V.B., Santvoort, H.C. van, Schelling, G.P. van der, Stommel, M.W.J., Tije, A.J. ten, Vos-Geelen, J. de, Wit, F., Wilmink, J.W., Laarhoven, H.W.M. van, Besselink, M.G., Dutch Pancreatic Canc Grp
Publikováno v:
HPB: The official journal of the International Hepato Pancreato Biliary Association, 22(2), 233-240. John Wiley and Sons Inc.
Hpb, 22, 2, pp. 233-240
International Hepato-Pancreato Biliary Association., 22(2), 233. John Wiley and Sons Inc.
HPB, 22(2), 233-240. ELSEVIER SCI LTD
HPB, 22(2), 233-240. John Wiley and Sons Inc.
HPB, 22(2), 233-240. John Wiley & Sons Inc.
Hpb, 22(2), 233-240. ELSEVIER SCI LTD
Mackay, T M, Smits, F J, Roos, D, Bonsing, B A, Bosscha, K, Busch, O R, Creemers, G-J, van Dam, R M, van Eijck, C H J, Gerhards, M F, de Groot, J W B, Groot Koerkamp, B, Haj Mohammad, N, van der Harst, E, de Hingh, I H J T, Homs, M Y V, Kazemier, G, Liem, M S L, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, van Santvoort, H C, van der Schelling, G P, Stommel, M W J, ten Tije, A J, de Vos-Geelen, J, Wit, F, Wilmink, J W, van Laarhoven, H W M, Besselink, M G & Dutch Pancreatic Cancer Group 2020, ' The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis ', HPB, vol. 22, no. 2, pp. 233-240 . https://doi.org/10.1016/j.hpb.2019.06.019
Hpb, 22, 233-240
Hpb, 22, 2, pp. 233-240
International Hepato-Pancreato Biliary Association., 22(2), 233. John Wiley and Sons Inc.
HPB, 22(2), 233-240. ELSEVIER SCI LTD
HPB, 22(2), 233-240. John Wiley and Sons Inc.
HPB, 22(2), 233-240. John Wiley & Sons Inc.
Hpb, 22(2), 233-240. ELSEVIER SCI LTD
Mackay, T M, Smits, F J, Roos, D, Bonsing, B A, Bosscha, K, Busch, O R, Creemers, G-J, van Dam, R M, van Eijck, C H J, Gerhards, M F, de Groot, J W B, Groot Koerkamp, B, Haj Mohammad, N, van der Harst, E, de Hingh, I H J T, Homs, M Y V, Kazemier, G, Liem, M S L, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, van Santvoort, H C, van der Schelling, G P, Stommel, M W J, ten Tije, A J, de Vos-Geelen, J, Wit, F, Wilmink, J W, van Laarhoven, H W M, Besselink, M G & Dutch Pancreatic Cancer Group 2020, ' The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis ', HPB, vol. 22, no. 2, pp. 233-240 . https://doi.org/10.1016/j.hpb.2019.06.019
Hpb, 22, 233-240
Contains fulltext : 226028.pdf (Publisher’s version ) (Closed access) BACKGROUND: The relation between type of postoperative complication and not receiving chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The aim
Autor:
Boorn, H.G. van den, Abu-Hanna, A., Mohammad, N.H., Hulshof, M.C.C.M., Gisbertz, S.S., Klarenbeek, B.R., Slingerland, M., Beerepoot, L.V., Rozema, T., Sprangers, M.A.G., Verhoeven, R.H.A., Oijen, M.G.H. van, Zwinderman, K.H., Laarhoven, H.W.M. van
Publikováno v:
Journal of the National Comprehensive Cancer Network, 19(4), 403-+. HARBORSIDE PRESS
The 21st Century Cures Act (Cures Act), signed into law in 2016, was designed to advance new therapies by modernizing clinical trials, funding research initiatives, and accelerating the development and use of health information technology. To analyze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2d92b5a3ae91181e7add0810ae7a94cb
https://hdl.handle.net/1887/3276864
https://hdl.handle.net/1887/3276864
Autor:
Braak, R.R.J.C. van den, Rijssen, L.B. van, Kleef, J.J. van, Vink, G.R., Berbee, M., Henegouwen, M.I.V., Bloemendal, H.J., Bruno, M.J., Burgmans, M.C., Busch, O.R.C., Coene, P.P.L.O., Coupe, V.M.H., Dekker, J.W.T., Eijck, C.H.J. van, Elferink, M.A.G., Erdkamp, F.L.G., Grevenstein, W.M.U. van, Groot, J.W.B. de, Grieken, N.C.T. van, Hingh, I.H.J.T. de, Hulshof, M.C.C.M., Ijzermans, J.N.M., Kwakkenbos, L., Lemmens, V.E.P.P., M. los, Meijer, G.A., Molenaar, I.Q., Nieuwenhuijzen, G.A.P., Noo, M.E. de, Poll-Franse, L.V. van de, Punt, C.J.A., Rietbroek, R.C., Roeloffzen, W.W.H., Rozema, T., Ruurda, J.P., Sandick, J.W. van, Schiphorst, A.H.W., Schipper, H., Siersema, P.D., Slingerland, M., Sommeijer, D.W., Spaander, M.C.W., Sprangers, M.A.G., Stockmann, H.B.A.C., Strijker, M., Tienhoven, G. van, Timmermans, L.M., Tjin-a-Ton, M.L.R., Velden, A.M.T. van der, Verhaar, M.J., Verkooijen, H.M., Vles, W.J., Vos-Geelen, J.M.P.G.M. de, Wilmink, J.W., Zimmerman, D.D.E., Oijen, M.G.H. van, Koopman, M., Besselink, M.G.H., Laarhoven, H.W.M. van, Dutch Pancreatic Canc Grp, Dutch Upper GI Canc Grp, PLCRC Working Grp
Publikováno v:
Acta Oncologica, 57(2), 195-202. Routledge/Taylor & Francis Group
Acta Oncologica, 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57, 2, pp. 195-202
Coebergh van den Braak, R R J, van Rijssen, L B, van Kleef, J J, Vink, G R, Berbee, M, van Berge Henegouwen, M I, Bloemendal, H J, Bruno, M J, Burgmans, M C, Busch, O R C, Coene, P P L O, Coupé, V M H, Dekker, J W T, van Eijck, C H J, Elferink, M A G, Erdkamp, F L G, van Grevenstein, W M U, de Groot, J W B, van Grieken, N C T, de Hingh, I H J T, Hulshof, M C C M, Ijzermans, J N M, Kwakkenbos, L, Lemmens, V E P P, Los, M, Meijer, G A, Molenaar, I Q, Nieuwenhuijzen, G A P, de Noo, M E, van de Poll-Franse, L V, Punt, C J A, Rietbroek, R C, Roeloffzen, W W H, Rozema, T, Ruurda, J P, van Sandick, J W, Schiphorst, A H W, Schipper, H, Siersema, P D, Slingerland, M, Sommeijer, D W, Spaander, M C W, Sprangers, M A G, Stockmann, H B A C, Strijker, M, van Tienhoven, G, Timmermans, L M, Tjin-a-Ton, M L R, van der Velden, A M T, Verhaar, M J, Verkooijen, H M, Vles, W J, de Vos-Geelen, J M P G M, Wilmink, J W, Zimmerman, D D E, van Oijen, M G H, Koopman, M, Besselink, M G H & van Laarhoven, H W M 2018, ' Nationwide comprehensive gastro-intestinal cancer cohorts : the 3P initiative ', Acta Oncologica, vol. 57, no. 2, pp. 195-202 . https://doi.org/10.1080/0284186X.2017.1346381
Acta oncologica (Stockholm, Sweden), 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57(2), 195. Informa Healthcare
Acta Oncologica, 57(2), 195-202
Acta Oncologica, 57, 195-202
Acta Oncologica, 57(2), 195-202. TAYLOR & FRANCIS LTD
Acta Oncologica, 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57, 2, pp. 195-202
Coebergh van den Braak, R R J, van Rijssen, L B, van Kleef, J J, Vink, G R, Berbee, M, van Berge Henegouwen, M I, Bloemendal, H J, Bruno, M J, Burgmans, M C, Busch, O R C, Coene, P P L O, Coupé, V M H, Dekker, J W T, van Eijck, C H J, Elferink, M A G, Erdkamp, F L G, van Grevenstein, W M U, de Groot, J W B, van Grieken, N C T, de Hingh, I H J T, Hulshof, M C C M, Ijzermans, J N M, Kwakkenbos, L, Lemmens, V E P P, Los, M, Meijer, G A, Molenaar, I Q, Nieuwenhuijzen, G A P, de Noo, M E, van de Poll-Franse, L V, Punt, C J A, Rietbroek, R C, Roeloffzen, W W H, Rozema, T, Ruurda, J P, van Sandick, J W, Schiphorst, A H W, Schipper, H, Siersema, P D, Slingerland, M, Sommeijer, D W, Spaander, M C W, Sprangers, M A G, Stockmann, H B A C, Strijker, M, van Tienhoven, G, Timmermans, L M, Tjin-a-Ton, M L R, van der Velden, A M T, Verhaar, M J, Verkooijen, H M, Vles, W J, de Vos-Geelen, J M P G M, Wilmink, J W, Zimmerman, D D E, van Oijen, M G H, Koopman, M, Besselink, M G H & van Laarhoven, H W M 2018, ' Nationwide comprehensive gastro-intestinal cancer cohorts : the 3P initiative ', Acta Oncologica, vol. 57, no. 2, pp. 195-202 . https://doi.org/10.1080/0284186X.2017.1346381
Acta oncologica (Stockholm, Sweden), 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57(2), 195. Informa Healthcare
Acta Oncologica, 57(2), 195-202
Acta Oncologica, 57, 195-202
Acta Oncologica, 57(2), 195-202. TAYLOR & FRANCIS LTD
Contains fulltext : 190038.pdf (Publisher’s version ) (Open Access) Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovati